Analysis BioNTech’s Legal Crossfire and Vaccine Pipeline Converge on a Pivotal Earnings Moment
BioNTech enters one of its most consequential weeks in recent memory, juggling a freshly approved COVID-19 vaccine, a deepening patent litigation campaign on two fronts, and second-quarter earnings due Tuesday...